Ergomed (ERGO)

 

ERGO Share PerformanceMore

52 week high216.90 28/02/17
52 week low117.00 16/09/16
52 week change 54.50 (37.59%)
4 week volume1,005,720 28/03/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Board and Management Changes

RNS Number: 3757C Ergomed plc 13 April 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Board and Management Changes London, UK - 13 April 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces Board and...

Director Deals - Ergomed Plc (ERGO)

Peter George, Non Executive Director, bought 100,000 shares in the company on the 3rd April 2017 at a price of 190.00p. The...

Director/PDMR Shareholding

RNS Number: 5275B Ergomed plc 04 April 2017 Ergomed Plc ("Ergomed" or the "Company") Director Dealing Ergomed, a profitable UK-based group dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, announces that on 3 April 2017, Mr Peter George, Chairman of the Company, bought 100,000 ordina...

Ergomed partner announces successful data

Ergomed has noted that co-development partner, Asarina Pharma, has today announced the publication of its phase IIa cli...

Partner Asarina Pharma announces successful data

RNS Number: 2708B Ergomed plc 03 April 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed notes co-development partner Asarina Pharma announces successful topline data for its Phase IIa Clinical Study with Sepranolone in Premenstrual Dysphoric Disorder ('PMDD') London, UK - 3 April 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Compan...

Ergomed revenues up 30%

Ergomed's revenues rose by 30% to 39.2 million in the year to the end of December and gross profit increased by 43% to 12...

Ergomed revenues up

Unaudited Preliminary Results for 2016

RNS Number: 6771A Ergomed plc 28 March 2017 PRESS RELEASE EMBARGOED FOR RELEASE 7.00am 28 MARCH 2017 Unaudited Preliminary Results for the year ended 31 December 2016 Top line revenue growth of 30% Gross profit up 43% New business won in 2016 increased 50% to 42 million Contracted backlog at 1 January 2017 of 70 million Multiple co...

Fundamental DataMore

P/E ratio153.462
EPS1.3
Dividend yield0 %

Equity Research (ERGO)

equity development
Ergomed Plc
12/04/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. 2016 perfectly highlighted the strengths of the...
equity development
Ergomed Plc
25/01/2017
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. The recent period end update for Ergomed confirmed...
equity development
Ergomed Plc
15/12/2016
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. It has unusually high revenue visibility, indeed...

Latest discussion posts More

  • Results webinar

    If you would like to hear management present the preliminary results for the year ended 31 December 2016 for Ergomed we will be hosting a webinar on Wednesday 29th March at ...
    22-Mar-2017
    equity_dev
  • See management present

    If you would like to hear Stephen Stamp, Chief Finance Officer, present on behalf of Ergomed he will be appearing at our next investor forum on the evening of Wednesday 25th of ...
    17-Jan-2017
    equity_dev
  • Webinar with management

    We will be hosting a webinar with the management of Ergomed tomorrow (Tuesday 27th September) at 11.15. There will be a presentation of the interim results lasting around ...
    26-Sep-2016
    equity_dev

Users' HoldingsMore

Users who hold Ergomed also hold..
GEMFIELDS33%
LLOYDS GRP.33%
INDIVIOR33%
OPG POWER22%
S & U22%

Codes & Symbols

ISINGB00BN7ZCY67
SymbolsERGO, LSE:ERGO, ERGO.L, ERGO:LN, LON:ERGO, XLON:ERGO